Statin use and breast cancer: prospective results from the Women's Health Initiative
- PMID: 16705124
- DOI: 10.1093/jnci/djj188
Statin use and breast cancer: prospective results from the Women's Health Initiative
Abstract
Background: Despite experimental observations suggesting that 3-hydroxy-3-methylglutaryl coenzyme A inhibitors (statins) have antitumor activity, clinical studies have reached mixed conclusions about the relationship between statin use and breast cancer risk.
Methods: To investigate associations between potency, duration of use, and type of statin used and risk of invasive breast cancer, we examined data for 156,351 postmenopausal women who were enrolled in the Women's Health Initiative. Information was collected on breast cancer risk factors and on the use of statins and other lipid-lowering drugs. Cox proportional hazards regression was used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs). Statistical tests were two-sided.
Results: Over an average follow-up of 6.7 years, 4383 invasive breast cancers were confirmed by medical record and pathology report review. Statins were used by 11,710 (7.5%) of the cohort. Breast cancer incidence was 4.09 per 1000 person-years (PY) among statin users and 4.28 per 1000 PY among nonusers. In multivariable models, the hazard ratio of breast cancer among users of any statin, compared with nonusers, was 0.91 (95% CI = 0.80 to 1.05, P = .20). There was no trend in risk by duration of statin use, with HR = 0.80 (95% CI = 0.63 to 1.03) for < 1 year of use, HR = 0.99 (95% CI = 0.80 to 1.23) for 1- < 3 years of use, and HR = 0.94 (95% CI = 0.75 to 1.18) for > or = 3 years of use. Hydrophobic statins (i.e., simvastatin, lovastatin, and fluvastatin) were used by 8106 women, and their use was associated with an 18% lower breast cancer incidence (HR = 0.82, 95% CI = 0.70 to 0.97, P = .02). Use of other statins (i.e., pravastatin and atorvastatin) or nonstatin lipid-lowering agents was not associated with breast cancer incidence.
Conclusions: Overall statin use was not associated with invasive breast cancer incidence. Our finding that use of hydrophobic statins may be associated with lower breast cancer incidence suggests possible within-class differences that warrant further evaluation.
Similar articles
-
A clinical review of statins and cancer: helpful or harmful?Pharmacotherapy. 2010 Feb;30(2):177-94. doi: 10.1592/phco.30.2.177. Pharmacotherapy. 2010. PMID: 20099992 Review.
-
The association between statins and cancer incidence in a veterans population.J Natl Cancer Inst. 2008 Jan 16;100(2):134-9. doi: 10.1093/jnci/djm286. Epub 2008 Jan 8. J Natl Cancer Inst. 2008. PMID: 18182618
-
Statin drugs and risk of advanced prostate cancer.J Natl Cancer Inst. 2006 Dec 20;98(24):1819-25. doi: 10.1093/jnci/djj499. J Natl Cancer Inst. 2006. PMID: 17179483
-
Statins and cancer development.Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1897-8. doi: 10.1158/1055-9965.EPI-05-0027. Cancer Epidemiol Biomarkers Prev. 2005. PMID: 16103434 Review.
-
Lipid-lowering drug use and breast cancer in older women: a prospective study.J Womens Health (Larchmt). 2003 Oct;12(8):749-56. doi: 10.1089/154099903322447710. J Womens Health (Larchmt). 2003. PMID: 14588125
Cited by
-
A review of research on the intersection between breast cancer and cardiovascular research in the Women's Health Initiative (WHI).Front Oncol. 2023 Mar 21;12:1039246. doi: 10.3389/fonc.2022.1039246. eCollection 2022. Front Oncol. 2023. PMID: 37025252 Free PMC article. Review.
-
Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer.BMC Cancer. 2023 Mar 9;23(1):224. doi: 10.1186/s12885-023-10631-w. BMC Cancer. 2023. PMID: 36894884 Free PMC article.
-
An Updated Systematic Review and Meta-Analysis on Association of Serum Lipid Profile With Risk of Breast Cancer Incidence.Int J Prev Med. 2022 Nov 23;13:142. doi: 10.4103/ijpvm.IJPVM_285_20. eCollection 2022. Int J Prev Med. 2022. PMID: 36618541 Free PMC article. Review.
-
Statin use in patients with hormone receptor-positive metastatic breast cancer treated with everolimus and exemestane.Cancer Med. 2023 Mar;12(5):5461-5470. doi: 10.1002/cam4.5369. Epub 2022 Oct 19. Cancer Med. 2023. PMID: 36263515 Free PMC article.
-
Lipid metabolism in ferroptosis and ferroptosis-based cancer therapy.Front Oncol. 2022 Aug 1;12:941618. doi: 10.3389/fonc.2022.941618. eCollection 2022. Front Oncol. 2022. PMID: 35978815 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical